venBio Select Advisor LLC Buys Puma Biotechnology Inc, Endocyte Inc, Iovance Biotherapeutics Inc, Sells Array BioPharma Inc, Bristol-Myers Squibb Company, MyoKardia Inc

San Francisco, CA, based Investment company venBio Select Advisor LLC buys Puma Biotechnology Inc, Endocyte Inc, Iovance Biotherapeutics Inc, ARMO BioSciences Inc, Biomarin Pharmaceutical Inc, Amicus Therapeutics Inc, Dynavax Technologies Corp, TG Therapeutics Inc, Pacira Pharmaceuticals Inc, Ascendis Pharma A/S, sells Array BioPharma Inc, Bristol-Myers Squibb Company, MyoKardia Inc, Cascadian Therapeutics Inc, NewLink Genetics Corp during the 3-months ended 2018-03-31, according to the most recent filings of the investment company, venBio Select Advisor LLC. As of 2018-03-31, venBio Select Advisor LLC owns 53 stocks with a total value of $2.1 billion. These are the details of the buys and sells.

For the details of venBio Select Advisor LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=venBio+Select+Advisor+LLC

These are the top 5 holdings of venBio Select Advisor LLC
  1. Immunomedics Inc (IMMU) - 16,939,461 shares, 11.83% of the total portfolio. Shares added by 5.45%
  2. Amicus Therapeutics Inc (FOLD) - 9,505,447 shares, 6.84% of the total portfolio. Shares added by 30.87%
  3. Biomarin Pharmaceutical Inc (BMRN) - 1,710,995 shares, 6.63% of the total portfolio. Shares added by 43.84%
  4. Iovance Biotherapeutics Inc (IOVA) - 8,078,505 shares, 6.53% of the total portfolio. Shares added by 53.78%
  5. Mirati Therapeutics Inc (MRTX) - 4,398,101 shares, 6.46% of the total portfolio.
New Purchase: Puma Biotechnology Inc (PBYI)

venBio Select Advisor LLC initiated holding in Puma Biotechnology Inc. The purchase prices were between $59.7 and $99.25, with an estimated average price of $74.88. The stock is now traded at around $53.70. The impact to a portfolio due to this purchase was 2.69%. The holding were 825,368 shares as of 2018-03-31.

New Purchase: Endocyte Inc (ECYT)

venBio Select Advisor LLC initiated holding in Endocyte Inc. The purchase prices were between $2.96 and $10.82, with an estimated average price of $5.52. The stock is now traded at around $14.39. The impact to a portfolio due to this purchase was 2.48%. The holding were 5,695,200 shares as of 2018-03-31.

New Purchase: ARMO BioSciences Inc (ARMO)

venBio Select Advisor LLC initiated holding in ARMO BioSciences Inc. The purchase prices were between $29.74 and $54.34, with an estimated average price of $42.29. The stock is now traded at around $50.00. The impact to a portfolio due to this purchase was 2.16%. The holding were 1,207,500 shares as of 2018-03-31.

New Purchase: Dynavax Technologies Corp (DVAX)

venBio Select Advisor LLC initiated holding in Dynavax Technologies Corp. The purchase prices were between $14.65 and $19.9, with an estimated average price of $17.27. The stock is now traded at around $15.95. The impact to a portfolio due to this purchase was 1.57%. The holding were 1,650,700 shares as of 2018-03-31.

New Purchase: Jounce Therapeutics Inc (JNCE)

venBio Select Advisor LLC initiated holding in Jounce Therapeutics Inc. The purchase prices were between $12.75 and $28.4, with an estimated average price of $21.98. The stock is now traded at around $7.89. The impact to a portfolio due to this purchase was 0.56%. The holding were 523,174 shares as of 2018-03-31.

New Purchase: Stemline Therapeutics Inc (STML)

venBio Select Advisor LLC initiated holding in Stemline Therapeutics Inc. The purchase prices were between $13.4 and $18.5, with an estimated average price of $15.59. The stock is now traded at around $17.60. The impact to a portfolio due to this purchase was 0.38%. The holding were 524,321 shares as of 2018-03-31.

Added: Iovance Biotherapeutics Inc (IOVA)

venBio Select Advisor LLC added to a holding in Iovance Biotherapeutics Inc by 53.78%. The purchase prices were between $8.1 and $19.5, with an estimated average price of $15.14. The stock is now traded at around $13.13. The impact to a portfolio due to this purchase was 2.28%. The holding were 8,078,505 shares as of 2018-03-31.

Added: Biomarin Pharmaceutical Inc (BMRN)

venBio Select Advisor LLC added to a holding in Biomarin Pharmaceutical Inc by 43.84%. The purchase prices were between $77.67 and $92.63, with an estimated average price of $85.82. The stock is now traded at around $96.54. The impact to a portfolio due to this purchase was 2.02%. The holding were 1,710,995 shares as of 2018-03-31.

Added: Amicus Therapeutics Inc (FOLD)

venBio Select Advisor LLC added to a holding in Amicus Therapeutics Inc by 30.87%. The purchase prices were between $13.76 and $17.12, with an estimated average price of $15.22. The stock is now traded at around $16.47. The impact to a portfolio due to this purchase was 1.61%. The holding were 9,505,447 shares as of 2018-03-31.

Added: TG Therapeutics Inc (TGTX)

venBio Select Advisor LLC added to a holding in TG Therapeutics Inc by 58.74%. The purchase prices were between $8.7 and $16.8, with an estimated average price of $12.78. The stock is now traded at around $13.70. The impact to a portfolio due to this purchase was 1.31%. The holding were 5,229,619 shares as of 2018-03-31.

Added: Pacira Pharmaceuticals Inc (PCRX)

venBio Select Advisor LLC added to a holding in Pacira Pharmaceuticals Inc by 102.11%. The purchase prices were between $29.98 and $46.35, with an estimated average price of $35.61. The stock is now traded at around $38.05. The impact to a portfolio due to this purchase was 1.29%. The holding were 1,715,072 shares as of 2018-03-31.

Added: Ascendis Pharma A/S (ASND)

venBio Select Advisor LLC added to a holding in Ascendis Pharma A/S by 22.74%. The purchase prices were between $38.98 and $68.04, with an estimated average price of $56.2. The stock is now traded at around $66.50. The impact to a portfolio due to this purchase was 1.2%. The holding were 2,063,336 shares as of 2018-03-31.

Sold Out: Bristol-Myers Squibb Company (BMY)

venBio Select Advisor LLC sold out a holding in Bristol-Myers Squibb Company. The sale prices were between $59.92 and $68.98, with an estimated average price of $64.33.

Sold Out: MyoKardia Inc (MYOK)

venBio Select Advisor LLC sold out a holding in MyoKardia Inc. The sale prices were between $41.3 and $61.1, with an estimated average price of $51.91.

Sold Out: Cascadian Therapeutics Inc (CASC)

venBio Select Advisor LLC sold out a holding in Cascadian Therapeutics Inc. The sale prices were between $3.56 and $10.06, with an estimated average price of $7.81.

Sold Out: NewLink Genetics Corp (NLNK)

venBio Select Advisor LLC sold out a holding in NewLink Genetics Corp. The sale prices were between $6.56 and $10.06, with an estimated average price of $7.87.

Sold Out: Incyte Corp (INCY)

venBio Select Advisor LLC sold out a holding in Incyte Corp. The sale prices were between $83.06 and $100.98, with an estimated average price of $90.16.

Sold Out: Cellectis SA (CLLS)

venBio Select Advisor LLC sold out a holding in Cellectis SA. The sale prices were between $27.78 and $35.19, with an estimated average price of $31.59.

Reduced: Array BioPharma Inc (ARRY)

venBio Select Advisor LLC reduced to a holding in Array BioPharma Inc by 64.84%. The sale prices were between $12.59 and $18.4, with an estimated average price of $16.02. The stock is now traded at around $18.04. The impact to a portfolio due to this sale was -2.94%. venBio Select Advisor LLC still held 1,922,655 shares as of 2018-03-31.

Reduced: Agenus Inc (AGEN)

venBio Select Advisor LLC reduced to a holding in Agenus Inc by 71.12%. The sale prices were between $3.51 and $6.04, with an estimated average price of $4.53. The stock is now traded at around $2.75. The impact to a portfolio due to this sale was -0.37%. venBio Select Advisor LLC still held 704,554 shares as of 2018-03-31.

Reduced: Veracyte Inc (VCYT)

venBio Select Advisor LLC reduced to a holding in Veracyte Inc by 84.09%. The sale prices were between $5.44 and $6.97, with an estimated average price of $6.19. The stock is now traded at around $8.90. The impact to a portfolio due to this sale was -0.27%. venBio Select Advisor LLC still held 119,680 shares as of 2018-03-31.



Here is the complete portfolio of venBio Select Advisor LLC. Also check out:

1. venBio Select Advisor LLC's Undervalued Stocks
2. venBio Select Advisor LLC's Top Growth Companies, and
3. venBio Select Advisor LLC's High Yield stocks
4. Stocks that venBio Select Advisor LLC keeps buying